$599
Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other, SGLT2i

Lexicon Q4 ’23 Earnings; Lexicon to Resubmit Sota T1DM NDA; MannKind INHALE-3 Initial Results; Praluent Receives Pediatric HeFH FDA Approval

Four cardiometabolic-related news items have been observed from Lexicon, MannKind, and Regeneron. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home